1. A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia (Moscow, Russia)
2. Non-governmental health care institution “Central Clinical Hospital № 2 them. N. A. Semashko” of the Russian Railways Open Joint-Stock Company (Moscow, Russia)

Keywords: irritable bowel syndrome, diagnostics, screening, biomarkers, stress, infl ammation

Abstract: The way to correct diagnosis in the Irritable bowel syndrome (IBS) in the most of cases is long and requires the number of laboratory and instrumental examinations. The diversity of the pathophysiology of IBS and heterogeneity within the syndrome nosology, including genetic predisposition, psychological aspects, visceral hypersensitivity, disorders of gastrointestinal motility, changes in the neuroendocrine system (brain-gut axis), low-grade infl ammation, imbalance of microbiota, etc. dictate the necessity of developing a workable routine tests for rapid and effi cient verifi cation of IBS. Considering IBS as a diagnosis of exclusion, we are on a path that requires a clear pharmacological justifi cation and, therefore, in most Western countries remains unacceptable. Therefore, the search for biomarkers of IBS is actual. Current publication describes current data available on this subject. Among them are the data of studies on the diagnostic value of markers of infl ammation in patients with IBS, elevated levels of stress agents in biological environments, and the development of special diagnostic panels of biomarkers, allowing to exclude a wide range of the diseases that have similar presentations to IBS.

• References total 19 ⇓ :: .
  1. Manning AP, Th ompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2(6138):653–654.
  2. Brian E. Lacy, Fermín Mearin, Lin Chang, William D. Chey, Anthony J. Lembo, Magnus Simren, and Robin Spiller. Bowel Disorders. Gastroenterology 2016;150:1393–1407.
  3. Engsbro A.L. et al. Patients suspected of irritable bowel syndrome – cross-sectional study exploring the sensitivity of Rome III criteria in primary care. Am J Gastroenterol. 2013; 108, 972–980.
  4. Stanisic V, and Quigley EM Th e overlap between IBS and IBD: what is it and what does it mean?. Expert Rev Gastroenterol Hepatol. 2014; 8, 139–145.
  5. Maev I. V., Cheremushkin S. V., Kucheryaviy Yu. A. Sindrom razdrazhennogo kishechnika. Rimskiye kriterii IV. O roli vistseral’noy giperchuvstvitel’nosti i sposobakh yeye korrektsii. Metodicheskoye posobiye [Irritable bowel syndrome. Roman criteria IV. On the role of visceral hypersensitivity and how to correct it. Toolkit]. Moscow, 2016.
  6. Maev I. V., Cheremushkin S. V., Kucheryaviy Yu.A., Cheremushkina N. V. Irritable bowel syndrome. Rome criteria IV. Consilium Medicum. 2016;18(8):79–85.
  7. Ivashkin V. T., Shelygin Yu.A., Baranskaya Ye.K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Ross z gastroenterol gepatol koloproktol 2017;27(5):76–93 DOI: 10.22416/1382–4376–2017–27–5–76–93
  8. Barbara G. IBS: biomarkers for IBS: ready for prime time? Nat Rev Gastroenterol Hepatol. 2015;12:9–10.
  9. Biomarkers Defi nitions Working Group (2001). Biomarkers and surrogate endpoints: preferred defi nitions and conceptual framework. Clin Pharmacol Th er. 2001; 69, 89–95.
  10. Hod K. et al. Assessment of high-sensitivity CRP as a marker of micro-infl ammation in irritable bowel syndrome. Neurogastroenterol Motil. 2011;23(12):1105–1110.
  11. Hauser G. et al. Erythrocyte sedimentation rate – possible role in determining the existence of the low grade infl ammation in Irritable Bowel Syndrome patients. Med Hypoth. 2012;78(6):818–820
  12. Kennedy P.J. et al. A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome. Psychological Medicine. 2014;44(14):3123–3134.
  13. FitzGerald L.Z. et al. Hypothalamic-pituitary-adrenal axis dysregulation in women with irritable bowel syndrome in response to acute physical stress. West J Nurs Res. 2009;31(7):818–836.
  14. Lembo A.J. et al. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Th er. 2009;29(8):834–842.
  15. Jones M.P. et al. A biomarker panel and psychological morbidity diff erentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Th er. 2014, 39, 426–437.
  16. Ohman L, Stridsberg M, Isaksson S, et al. Altered levels of fecal chromogranins and secretogranins in IBS: relevance for pathophysiology and symptoms? Am J Gastroenterol. 2012;107:440–447.
  17. Von Arnim U, Wex T, Ganzert C, et al. Fecal calprotectin: a marker for clinical diff erentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97–103.
  18. Jonefj äll B, Öhman L, Simrén M, et al. IBS-like symptoms in patients with ulcerative colitis in deep remission are associated with increased levels of serum cytokines and poor psychological wellbeing. Infl amm Bowel Dis. 2016;22:2630–2640.
  19. Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude infl ammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.

Full text is published :
Maev I. V., Cheremushkin S. V., Kucheryavyy Y. A., Cheremushkina N. V. Biomarkers in the diagnosis of irritable bowel syndrome, what is the reality? Experimental and Clinical Gastroenterology. 2018;158(10): 86–91. DOI: 10.31146/1682-8658-ecg-158-10-86-91
Read & Download full text